DMP.DEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 21:34):

Stats
本日の出来高	3 950.00
平均出来高	20 696.00
時価総額	1.69B
EPS	€0 ( 2024-03-27 )
次の収益日	( €0 ) 2024-05-13
Last Dividend	€1.050 ( 2023-06-15 )
Next Dividend	€0 ( N/A )
P/E	17.78
ATR14	€0.0880 (0.28%)

ボリューム相関

長: -0.27 (neutral)

短: 0.57 (weak)

Signal:(49.471) Neutral

Dermapharm Holding SE 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Dermapharm Holding SE 相関 - 通貨/商品

0.32
( neutral )

0.34
( neutral )

0.00
( neutral )

0.21
( neutral )

0.31
( neutral )

-0.30
( neutral )

Dermapharm Holding SE 財務諸表

Annual	2022
収益:	€1.02B
総利益:	€660.83M (64.49 %)
EPS:	€2.49

FY	2022
収益:	€1.02B
総利益:	€660.83M (64.49 %)
EPS:	€2.49

FY	2021
収益:	€942.91M
総利益:	€620.69M (65.83 %)
EPS:	€3.89

FY	2020
収益:	€793.83M
総利益:	€463.48M (58.39 %)
EPS:	€1.590

Financial Reports:

No articles found.

Dermapharm Holding SE Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€1.050 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Dermapharm Holding SE Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.09 - Increase likely (41.71%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.770	2019-06-05
Last Dividend	€1.050	2023-06-15
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	€5.67	--
Avg. Dividend % Per Year	0.00%	--
Score	3.23	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.09
Div. Directional Score	8.93	--

Next Divdend (Est)
(2025-03-31)

€0.606 Estimate 3.09 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.23

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
HNR1.DE	Ex Dividend Junior	2023-05-04	Annually	0.00%
SDF.DE	Ex Dividend Junior	2023-05-11	Annually	0.00%
CEK.DE	No Dividend Player	2023-11-06	Sporadic	0.00%
KRN.DE	Ex Dividend Knight	2023-05-24	Annually	0.00%
TTK.DE	Ex Dividend Junior	2023-05-25	Annually	0.00%
DWD.DE	Ex Dividend Junior	2023-07-28	Quarterly	0.00%
MZX.DE	Ex Dividend Knight	2023-06-08	Sporadic	0.00%
8TRA.DE	Ex Dividend Junior	2023-06-02	Annually	0.00%
XGR2.DE	Ex Dividend Junior	2023-06-08	Annually	0.00%
FPMB.DE	Ex Dividend King	2023-10-12	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0821	1.500	8.36	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0440	1.200	8.53	10.00	[0 - 0.3]
returnOnEquityTTM	0.174	1.500	9.17	10.00	[0.1 - 1]
payoutRatioTTM	0.595	-1.000	4.05	-4.05	[0 - 1]
currentRatioTTM	1.857	0.800	5.72	4.57	[1 - 3]
quickRatioTTM	0.798	0.800	-0.0114	-0.00913	[0.8 - 2.5]
cashRatioTTM	0.347	1.500	9.18	10.00	[0.2 - 2]
debtRatioTTM	0.508	-1.500	1.539	-2.31	[0 - 0.6]
interestCoverageTTM	4.32	1.000	9.51	9.51	[3 - 30]
operatingCashFlowPerShareTTM	5.18	2.00	8.27	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.45	2.00	7.77	10.00	[0 - 20]
debtEquityRatioTTM	2.01	-1.500	1.968	-2.95	[0 - 2.5]
grossProfitMarginTTM	0.642	1.000	2.64	2.64	[0.2 - 0.8]
operatingProfitMarginTTM	0.192	1.000	8.15	8.15	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.254	1.000	9.70	9.70	[0.2 - 2]
assetTurnoverTTM	0.536	0.800	9.76	7.81	[0.5 - 2]
Total Score				10.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.75	1.000	8.31	0	[1 - 100]
returnOnEquityTTM	0.174	2.50	9.47	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.45	2.00	8.52	10.00	[0 - 30]
dividendYielPercentageTTM	3.35	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.18	2.00	8.27	10.00	[0 - 30]
payoutRatioTTM	0.595	1.500	4.05	-4.05	[0 - 1]
pegRatioTTM	13.67	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.241	1.000	6.48	0	[0.1 - 0.5]
Total Score				7.09

Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.